Determinants of sensitivity to DZNep induced Apoptosis in multiple myeloma cells

Determinants of sensitivity to DZNep induced Apoptosis in multiple myeloma cells

10.1371/journal.pone.0021583

Saved in:

Bibliographic Details
Main Authors:	Xie, Z., Bi, C., Cheong, L.L., Liu, S.C., Huang, G., Zhou, J., Yu, Q., Chen, C.-S., Chng, W.J.
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	2014
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/116973
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

miRNA deregulation in multiple myeloma
by: Bi C.L., et al.
Published: (2018)

MicroRNA: Important player in the pathobiology of multiple myeloma
by: Bi C., et al.
Published: (2018)

The Molecular Biology of Multiple Myeloma
by: Chng, W.J., et al.
Published: (2016)

MMSET: Role and therapeutic opportunities in multiple myeloma
by: Xie Z., et al.
Published: (2018)

Malignant pleural effusion in a patient with multiple myeloma
by: Lau, L.G., et al.
Published: (2016)

Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in t(4;14) multiple myeloma
by: Xie, Z., et al.
Published: (2014)

2,5-Dihydroxyacetophenone Induces Apoptosis of Multiple Myeloma Cells by Regulating the MAPK Activation Pathway
by: Ko, J.-H, et al.
Published: (2020)

Potential clinical application of genomics in multiple myeloma
by: Soekojo, C.Y, et al.
Published: (2020)

P53 abnormalities and potential therapeutic targeting in multiple myeloma
by: Teoh P.J., et al.
Published: (2018)

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
by: Bi, C, et al.
Published: (2020)

Implications of heterogeneity in multiple myeloma
by: De Mel S., et al.
Published: (2018)

Clinical profiles of multiple myeloma in asia-an asian myeloma network study
by: Kim, K., et al.
Published: (2016)

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival
by: Reghunathan, R., et al.
Published: (2014)

IDENTIFICATION OF A NOVEL AGENT THAT CAN SUPPRESS PROLIFERATION, INDUCE APOPTOSIS AND OVERCOME CHEMORESISTANCE IN MULTIPLE MYELOMA
by: RADHAMANI KANNAIYAN
Published: (2014)

TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep)
by: Cheng, L.L., et al.
Published: (2014)

Inhibition of Proliferation and Induction of Apoptosis in Multiple Myeloma Cell Lines by CD137 Ligand Signaling
by: Gullo C., et al.
Published: (2018)

Immunotherapy in Multiple Myeloma
by: Soekojo, Cinnie Yentia, et al.
Published: (2022)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
by: Teoh P.J., et al.
Published: (2020)

The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: An analysis of the Singapore multiple myeloma study group
by: Tan, D., et al.
Published: (2016)

Management of multiple myeloma in asia: Resource-stratified guidelines
by: Tan, D., et al.
Published: (2016)

Natural history and prognostic factors at first relapse in multiple myeloma
by: Wang, C., et al.
Published: (2021)

IMWG consensus on risk stratification in multiple myeloma
by: Chng, W.J., et al.
Published: (2016)

Metabolic Vulnerabilities in Multiple Myeloma
by: Lim, Julia SL, et al.
Published: (2022)

Centrosomes and myeloma; aneuploidy and proliferation
by: Chng, W.J., et al.
Published: (2016)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
by: Zhou, Jianbiao, et al.
Published: (2022)

Formononetin regulates multiple oncogenic signaling cascades and enhances sensitivity to bortezomib in a multiple myeloma mouse model
by: Kim, C., et al.
Published: (2021)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
by: Chung, T.-H., et al.
Published: (2014)

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL
by: Ueno, S., et al.
Published: (2011)

Clinical and biological significance of RAS mutations in multiple myeloma
by: Chng, W.J., et al.
Published: (2011)

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: Efficacy, biomarker and drug combinations
by: Lim, S.L., et al.
Published: (2021)

P53 GENOMIC STATUS REGULATES SENSITIVITY OF GASTRIC CANCER CELLS TO THE HISTONE METHYLATION INHIBITOR 3-DEAZANEPLANOCIN A (DZNEP)
by: CHENG LAI LING
Published: (2012)

A unique rhinologic manifestation of multiple myeloma
by: Seah, Jun Jie, et al.
Published: (2022)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
by: Davies, FE, et al.
Published: (2023)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
by: Davies, FE, et al.
Published: (2023)

Targeting nf-κb signaling for multiple myeloma
by: Wong, A.H.-H., et al.
Published: (2021)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
by: Zhou, Jianbiao, et al.
Published: (2022)

Management of treatment-emergent peripheral neuropathy in multiple myeloma
by: Richardson, P.G., et al.
Published: (2016)

GENOME-WIDE PHARMACOLOGIC UNMASKING IDENTIFIES TUMOR SUPPRESSOR MICRORNAS IN MULTIPLE MYELOMA
by: BI CHONGLEI
Published: (2016)

Unraveling genomic instability in multiple myeloma - Mechanisms, biological and clinical implications
by: CHNG WEE JOO
Published: (2011)

CAR T-cell therapy in multiple myeloma: more room for improvement
by: Teoh, Phaik Ju, et al.
Published: (2021)